Phospholipase D (PLD) is activated by a number of extracellular signaling factors including growth factors, neurotransmitters, and hormones (1, 2) . PLD-mediated phospholipid hydrolysis modulates membrane composition and produces second messenger molecules (3) . It plays a key role in cellular signaling processes leading to cytoskeletal organization, vesicle trafficking, and cell proliferation and differentiation. Previously, we demonstrated that parathyroid hormone (PTH) stimulates PC breakdown and PLD activity, as assessed by transphosphatidylation, in UMR-106 osteoblastic cells (4) . We have also shown that calcium, mitogen-activated protein kinase (MAPK), small G proteins, and Gα12/Gα13 heterotrimeric G proteins are involved in regulation of the PTH-stimulated PLD activity (5, 6) . In the latter studies, transphosphatidylation of ethanol, a process directly mediated by PLD, was used as an indicator of PLD activity. Comparisons between results of experiments in which either PC hydrolysis or transphosphatidylation was assayed revealed that the PTH-or phorbol-12,13-dibutyrate (PDBu)-stimulated effects, as measured by transphosphatidylation, were greater than those from PC hydrolysis. These data suggested that additional phospholipid species might be involved in the actions of PTH and PDBu. PE is another major phospholipid component of biological membranes. Kiss and Anderson (7) have shown that phorbol ester stimulates PE hydrolysis in leukemic HL-60, NIH 3T3, and BHK-21 cells. Nakamura et al. (8) determined that both PC and PE are substrates for PLD activity in bovine kidney. However, in other studies, PLD1 and PLD2 showed little (9) or no (10) activity on PE. An N-acylPE-hydrolyzing PLD also has been identified in mammalian cells (11, 12) . To address the question of whether ethanolamine-containing phospholipids, and specifically PE, could be hydrolyzed in addition to PC in response to PTH or PDBu in UMR-106 cells, we determined the effects of PTH and PDBu on hydrolysis of PE as well as hydrolysis of PC in dual-labeled UMR-106 cells.
EXPERIMENTAL PROCEDURES
Materials. UMR-106 osteoblastic cells were purchased from American Type Culture Collection (Manassas, VA). PTH was from Bachem (Torrance, CA). PDBu was from Sigma Chemical Co. (St. Louis, MO). [Methyl-µCi/mL). Radioactivity in PC and PE reached a plateau by this time point. After the labeling, cells were washed with DMEM and then incubated in 2 mL serum-free DMEM containing 20 mM HEPES buffer and 0.1% BSA in the absence or presence of either PTH or PDBu. Following incubation at the indicated times and concentrations, media were quickly removed, and radioactivity in the media was determined by dual channel scintillation spectrometry.
To determine the specificity of the incorporation of the choline and ethanolamine labels, 3 H and 14 C were determined in both the choline and ethanolamine released into the medium. A 20 µL aliquot of the medium was spotted on a TLC plate. Choline and ethanolamine were separated using 0.5% NaCl/CH 3 OH/NH 4 OH (50:50:5) and visualized by exposing the plate to iodine. The plates were autoradiographed for 2 wk at -80°C. The choline (R f = 0.14) and ethanolamine (R f = 0.5) bands were scraped and counted by liquid scintillation.
To determine whether PE was affected by the treatments, cells were labeled with 14 C-ethanolamine, treated with PTH or PDBu for 60 min, and then scraped into ice-cold methanol. The lipids were then extracted. The organic phase was dried under N 2 , reequilibrated in 100 µL CHCl 3 /CH 3 OH (9:1), and 50 µL was spotted on a TLC plate. PE (R f = 0.54) was separated using CHCl 3 /CH 3 OH/NH 4 OH (65:25:5) as the running solvent. Samples were spiked with a PE standard (1-palmitoyl-2-oleoyl-snglycero-3-phosphoethanolamine; Avanti Polar Lipids, Alabaster, AL). The PE standard was visualized with iodine and radioactivity in the band determined.
Transfection. 0.5 µg each of pcDNA 3 (parental vector), dn PLD1 or dn PLD2 were precomplexed with Lipofectamine Plus® reagent (Life Technologies, Rockville, MD) in OPTI-MEM (Gibco BRL, Gaithersburg, MD) in the absence of antibiotics and serum. Cells were incubated with the constructs for 3 h at 37°C in a 5% CO 2 atmosphere, after which 1 mL of OPTI-MEM medium containing 5% FBS and 1% penicillin/ streptomycin was added to each of the culture dishes. Medium was changed after 6 h, and incubation continued until 48 h.
Transphosphatidylation. Cells were labeled with [ 14 C]-palmitic acid (0.25 µCi/mL) for the final 24 h of the incubation with the constructs described above. Cells were washed and then treated with PTH for 30 min in DMEM containing 20 mM HEPES, 0.1% BSA, and 1% absolute ethanol. To terminate the reaction, media were quickly removed, and 1 mL ice-cold methanol was added to cells. Cells were scraped into chloroform and lipids extracted using the method of Folch et al. (14) . The extract containing lipids was dried under nitrogen, lipids were re-equilibrated in 100 µL CHCl 3 /CH 3 OH (9:1), of which 50 µL was spotted on a TLC plate, and a 10-µL aliquot was used to determine total lipid radioactivity. Phosphatidylethanol (R f = 0.57) was separated from the total lipid fraction by TLC using CHCl 3 /CH 3 OH/CH 3 COOH (70:10:2) as the running solvent. A 1,2-dipalmitoyl-sn-glycero-3-phosphoethanol standard was run concurrently. Lipids were visualized by exposure to iodine vapor. For autoradiography, TLC plates were incubated at -70°C for 72 h. The phosphatidylethanol bands were scraped, and radioactivity was determined by liquid scintillation counting. The 14 C radioactivity recovered in phosphatidylethanol at the end of the treatments was expressed as the percentage of total 
RESULTS AND DISCUSSION
To determine whether both PC and ethanolamine-containing phospholipids were serving as substrates for PLD activity stimulated by the agonists, UMR-106 cells were dual-labeled with [methyl-3 H]choline chloride and [2-14 C]ethanolamine hydrochloride, and phospholipid hydrolysis was assessed as described in the Experimental Procedures section. In an experiment designed to test this (Fig. 1) , media from the incubations were chromatographed to determine whether any of the 3 Hcholine label appeared in the ethanolamine and, conversely, whether any of the 14 C-ethanolamine label appeared in the choline. Treating the cells with PTH (10 nM) or PDBu (500 nM) increased medium 14 C-ethanolamine (Fig. 1A ) and 3 Hcholine (Fig. 1D) . The labeling was selective, in that there was no significant 3 H label in the ethanolamine fraction (Fig. 1B ) and no significant 14 C label in the choline fraction (Fig. 1C) . For subsequent experiments, media were not fractionated, and 14 C and 3 H were used as indicators of ethanolamine-containing phospholipids and PC hydrolysis, respectively.
To determine whether PE was hydrolyzed in response to treatment with PTH (10 nM) or PDBu (500 nM), 14 Cethanolamine-labeled lipids were separated by TLC as described in the Experimental Procedures section. Treatment for 60 min with either agonist resulted in a significant decrease in radioactive PE (Fig. 2) .
To confirm that the effects on lipid hydrolysis were mediated through PLD, cells were transfected with catalytically inactive constructs of PLD1 or PLD2 that previously have been used successfully as putative dominant negatives (16) (17) (18) . Both PLD1 and PLD2 constructs were used, since both isoforms are present in the UMR-106 cells (5) . pcDNA3 served as a control for transfection. Effects of PTH were then determined. Initial experiments were carried out to confirm that the constructs inhibited PTH-stimulated transphosphatidylation. Data from a representative experiment are shown (Fig. 3A) . The constructs inhibited PTH-stimulated hydrolysis of ethanolamine-containing phospholipids (Fig. 3B) and PC (Fig. 3C) , indicating that the effects on phospholipid hydrolysis were mediated through PLD. Results are mean ± SE of triplicate determinations for each treatment. *P < 0.05, **P < 0.01, ***P < 0.001 vs. respective controls. The ratio of 14 C to 3 H radioactivity, which was unaffected by the stimulators, is presented in panel E.
